Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis.
Lewiecki, E Michael; Miller, Paul D; Harris, Steve T; Bauer, Douglas C; Davison, K Shawn; Dian, Larry; Hanley, David A; McClung, Michael R; Yuen, Chui K; Kendler, David L.
J Clin Densitom
; 17(4): 490-5, 2014 Oct-Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24206867
Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Short-term daily teriparatide in patients with rheumatoid arthritis.
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.
Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient.
Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review.
[Secondary osteoporosis UPDATE. Treatment of male osteoporosis. Testosterone replacement therapy etc].
Antiresorptives and osteonecrosis of the jaw.